


ESMO Virtual Congress 2020 Industry Satellite Symposium

In-house NGS testing and treatment paradigm is optimal for patients



NGS Biomarker testing: time matters - No longer need to wait for weeks, as this can now happen within days.

Genomic profiling by means of NGS is driving the precision oncology research and also its implementation to routine patient care. There are however many aspects and constant new developments which play role in us making sure we are using it to maximum patient benefits. Is liquid biopsy a true alternative? What is the best technology for individual biomarker types – for example fusions, and what truly is important from the clinician point of view?

In this educational satellite symposium we will touch upon many of these and hopefully initiate some fruitful discussion and learnings.

On demand from Monday 14th September - Tuesday 29th September 2020.

Live Q&A Session: Wednesday 23rd September, 10.45 – 11.15 CEST.



Genomic profiling is driving the precision oncology

Philip Jermann, Institute of Medical Genetics and Pathology of Basel, Basel, Switzerland



Lung cancer diagnostic test needs: perspective from a thoracic oncologist

Gabriela Fernandes, Managing Director, Pulmonology Department, Centro Hospitalar, Universitário de São João, Porto, Portugal



Establishment of a large-scale Asian genomic screening platform to identify non-small cell lung cancer with rare driver oncogenes and clarify drug resistant mechanisms

Koichi Goto, Department Head of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan



NTRK, RET and other fusion biomarkers testing: Latest developments

Philip Jermann, Institute of Medical Genetics and Pathology of Basel, Basel, Switzerland

ThermoFisher
SCIENTIFIC